|
1
|
Naito S, Tatsugami K, Shinohara N, Tomita
Y, Mizokami A, Fujisawa M, Hashine K, Nishikido M, Nakagawa M,
Tsukamoto T and Akaza H: Final results of a phase II study of S-1
in patients with cytokine-refractory metastatic renal cell
carcinoma. Jpn J Clin Oncol. 44:122–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Japanese Urological Association: Guideline
on renal cell carcinoma 66–75. 2011 http://www.urol.or.jp/info/guideline/data/07_kidney_cancer_2011.pdfAccessed.
March 17–2015.
|
|
3
|
Ljungberg B, Albiges L, Bensalah K, Bex A,
Giles RH, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS,
Powles T, et al: Guideline on renal cell carcinoma. European
Association of Urology. http://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma_LR1.pdfAccessed.
March 17–2015.
|
|
4
|
Knox JJ, Barrios CH, Kim TM, Cosgriff T,
Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD,
et al: Final overall survival analysis for the phase II RECORD-3
study of first-line everolimus followed by sunitinib versus
first-line sunitinib followed by everolimus in metastatic RCC. Ann
Oncol. 28:1339–1345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Barrios CH, Kim TM, Falcon S,
Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Pha
SY, et al: Phase II randomized trial comparing sequential
first-line everolimus and second-line sunitinib versus first-line
sunitinib and second-line everolimus in patients with metastatic
renal cell carcinoma. J Clin Oncol. 32:2765–2771. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoshinaga A and Kamata S: Long survival in
a patient with advanced ureteral carcinoma treated with TIN Regimen
(Paclitaxel, Ifosfamide, Nedaplatin) and Radiotherapy: A Case
Report. Hinyokika Kiyo. 60:435–437. 2014.(In Japanese). PubMed/NCBI
|
|
7
|
Hoshi S, Ohyama C, Ono K, Takeda A,
Yamashita S, Yamato T, Itoh A, Satoh M, Saito S, Okada Y, et al:
Gemcitabine plus carboplatin; and gemcitabine, docetaxel and
carboplatin combined chemotherapy regimens in patients with
metastatic urothelial carcinoma previously treated with a
platinum-based regimen: Preliminary report. Int J Clin Oncol.
9:125–129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Procopio G, Testa I, Iacovelli R, Grassi
P, Verzoni E, Garanzini E, Colecchia M, Torelli T and De Braud F:
Treatment of collecting duct carcinoma: Current status and future
perspectives. Anticancer Res. 34:1027–1030. 2014.PubMed/NCBI
|
|
9
|
Biondani P, Verzoni E, Torri V, Porcu L,
Grassi P, Testa I, DE Braud F and Procopio G: Sequential tyrosine
kinase inhibitors (TKIs) in metastatic renal cell carcinoma:
Results from a large cohort of patients. Anticancer Res.
34:2395–2398. 2015.
|
|
10
|
Bracarda S, Castellano D, Procopio G,
Sepúlveda JM, Sisani M, Verzoni E and Schmidinger M: Axitinib
safety in metastatic renal cell carcinoma: Suggestions for daily
clinical practice based on case studies. Expert Opin Drug Saf.
13:497–510. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Procopio G, Verzoni E, Biondani P, Grassi
P, Testa I, Garanzini E and de Braud F: Rationale and protocol of
RESORT, a randomized, open-label, multicenter phase II study to
evaluate the efficacy of sorafenib in patients with advanced renal
cell carcinoma after radical resection of the metastases. Tumori.
100:e28–e30. 2014.PubMed/NCBI
|
|
12
|
Grüenwald V, Lin X, Kalanovic D and
Simantov R: Early tumor shrinkage (eTS) as a predictive and
prognostic factor in metastatic renal cell carcinoma (mRCC). J Clin
Oncol. 33 (suppl; abstr 4551):2015.
|
|
13
|
Motzer R, Hutson T, Glen H, Michaelson D,
Molina AM, Eisen T, Jassem J, Zolnierek J, Maroto P, Mellado B, et
al: Randomized phase II, three-arm trial of lenvatinib (LEN),
everolimus (EVE) and LEN+EVE in patients (pts) with metastatic
renal cell carcinoma (mRCC). J Clin Oncol. 33 (suppl; abstr
4506):2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choueiri TK, Figueroa DJ, Fay AP,
Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C, Benson P, Ho
TH, et al: Correlation of PD-L1 tumor expression and treatment
outcomes in patients with renal cell carcinoma receiving sunitinib
or pazopanib: Results from COMPARZ, a randomized controlled trial.
Clin Cancer Res. 21:1071–1077. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Armstrong AJ, Broderick S, Eisen T,
Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins
RE, Hainsworth JD, et al: Final clinical results of a randomized
phase II international trial of everolimus vs. sunitinib in
patients with metastatic non-clear cell renal cell carcinoma
(ASPEN). J Clin Oncol. 33 (suppl; abstr 4507):2015.
|
|
16
|
Thoma C: Kidney cancer: CheckMate for
advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor
survival. Nat Rev Clin Oncol. 12:6212015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Michel Ortega RM and Drabkin HA: Nivolumab
in renal cell carcinoma. Expert Opin Biol Ther. 15:1049–1060. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Choueiri TK, Fishman M, Escudier B,
McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL,
McNeel DG, Curti BD, et al: Immunomodulatory activity of nivolumab
in metastatic renal cell carcinoma. Clin Cancer Res May.
11:2016.(Epub ahead of print).
|
|
20
|
Nadal R, Amin A, Geynisman DM, Voss Martin
HM, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott
DF, et al: Efficacy and safety of endothelial growth factor
receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed
cell death 1 (PD-1) inhibitor treatment in patients with metastatic
clear cell renal cell carcinoma (mccRCC). J Clin Oncol.
33:45662015.
|
|
21
|
Ho TH, Millis SZ, Bryant D, Gatalica Z,
Reddy SK, Stanton ML, Castle EP, Joseph RW and Vogelzang NJ:
Molecular analysis of sarcomatoid renal cell carcinoma (sRCC). J
Clin Oncol. 33 (suppl; abstr 4556):2015. View Article : Google Scholar
|
|
22
|
Albiges L, Fay AP, Xie W, Krajewski K,
McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B
and Choueiri TK: Efficacy of targeted therapies after PD-1/PD-L1
blockade in metastatic renal cell carcinoma. Eur J Cancer.
51:2580–2586. 2015. View Article : Google Scholar : PubMed/NCBI
|
